ONTX Onconova Therapeutics Inc.

3.69
-0.01  -0%
Previous Close 3.7
Open 3.7
Price To Book 1.93
Market Cap 20937872
Shares 5,674,220
Volume 50,247
Short Ratio
Av. Daily Volume 145,192

NewsSee all news

  1. Onconova Therapeutics, Inc. to Present Corporate Update at the BIO CEO & Investor Conference in New York City
  2. Advancements in the Treatment of Myelodysplastic Syndromes and RAS-Mutated Lung Cancers to be Presented by Key Opinion Leaders on Thursday, February 7, 2019, in New York City
  3. Onconova Therapeutics, Inc. to Present at the NobleCON 15th Annual Investor Conference in Fort Lauderdale, FL
  4. Bucks County biopharm firm names new CEO
  5. Onconova Therapeutics Promotes Dr. Steven M. Fruchtman to Chief Executive Officer

SEC filingsSee all SEC filings

  1. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19604968
  2. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19604760
  3. 8-K - Current report 19527660
  4. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19504494
  5. 8-K - Current report 181212809

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 Special Protocol Assessment (SPA) submission announced January 2, 2019.
Oral Rigosertib and azacitidine
First-line HR-MDS (high risk myelodysplastic syndromes)
Phase 3 trial to be completed 2H 2019.
IV Rigosertib - INSPIRE
2nd-line HR-MDS (high risk myelodysplastic syndromes)

Latest News

  1. Onconova Therapeutics, Inc. to Present Corporate Update at the BIO CEO & Investor Conference in New York City
  2. Advancements in the Treatment of Myelodysplastic Syndromes and RAS-Mutated Lung Cancers to be Presented by Key Opinion Leaders on Thursday, February 7, 2019, in New York City
  3. Onconova Therapeutics, Inc. to Present at the NobleCON 15th Annual Investor Conference in Fort Lauderdale, FL
  4. Bucks County biopharm firm names new CEO
  5. Onconova Therapeutics Promotes Dr. Steven M. Fruchtman to Chief Executive Officer
  6. Onconova Submits Special Protocol Assessment (SPA) to FDA for Phase 3 Trial of Oral Rigosertib in Combination with Azacitidine (Vidaza®) for First-Line Myelodysplastic Syndromes (MDS)
  7. Onconova to Meet Investors and Potential Partners at China Focus and the 37th Annual J.P. Morgan Healthcare Conferences in San Francisco
  8. Onconova Welcomes Avi Oler, JD, MBA, as Vice President, Corporate Development and General Counsel
  9. Onconova Highlights Results from Phase 2 Trial of Oral Rigosertib In Combination with Azacitidine (Vidaza®) in Myelodysplastic Syndromes (MDS) at the 2018 ASH Annual Meeting
  10. Edited Transcript of ONTX earnings conference call or presentation 13-Nov-18 2:00pm GMT
  11. Onconova Welcomes Richard (Ric) Woodman, M.D., as Chief Medical Officer (CMO)
  12. Onconova Therapeutics (ONTX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
  13. Today's Research Reports on Trending Tickers: Onconova Therapeutics and Cellectar Biosciences
  14. Bucks County biopharm firm implements reverse stock split

SEC Filings

  1. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19604968
  2. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19604760
  3. 8-K - Current report 19527660
  4. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19504494
  5. 8-K - Current report 181212809
  6. 10-Q - Quarterly report [Sections 13 or 15(d)] 181184927
  7. 8-K - Current report 181175335
  8. 8-K - Current report 181121404
  9. 8-K - Current report 181086110
  10. 10-Q - Quarterly report [Sections 13 or 15(d)] 181018936